Prospect of Anterior Gradient 2 homodimer inhibition via repurposing FDA-approved drugs using structure-based virtual screening

Prospect of Anterior Gradient 2 homodimer inhibition via repurposing FDA-approved drugs using structure-based virtual screening

Anterior Gradient 2 (AGR2) has recently been reported as a tumor biomarker in various cancers, i.e., breast, prostate and lung cancer. Predominantly, AGR2 exists as a homodimer via a dimerization domain (E60-K64); after it is self-dimerized, it helps FGF2 and VEGF to homo-dimerize and promotes the a...

Full description

Bibliographic Details
Published in:Molecular Diversity
Main Author: Ullah S.; Khan S.U.; Khan A.; Junaid M.; Rafiq H.; Htar T.T.; Zhao Y.; Shah S.A.A.; Wadood A.
Format: Article
Language:English
Published: Springer Science and Business Media Deutschland GmbH 2022
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85132454223&doi=10.1007%2fs11030-021-10263-x&partnerID=40&md5=3a0109e4b9ef9c1d7915bcc977690c4d

Internet

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85132454223&doi=10.1007%2fs11030-021-10263-x&partnerID=40&md5=3a0109e4b9ef9c1d7915bcc977690c4d

Similar Items